Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Angiodynamics, Inc. (ANGO)
:ANGO
Holding ANGO?
Track your performance easily
Earnings Data
Report Date
Apr 03, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 04, 2019
|% Change Since: 35.85%
|Next Earnings Date:Sep 27, 2018
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in revenue growth and profitability, especially within the Med Tech segment, driven by innovations like AlphaVac and NanoKnife. However, challenges persist in Med Device revenue stagnation and manufacturing transition costs, tempering overall financial improvements.Company Guidance
During the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call, the company provided guidance indicating strong financial performance, with total worldwide revenue reaching $73 million, a 9% year-over-year increase. The Med Tech segment experienced robust growth of 25%, driven by products like Auryon and mechanical thrombectomy devices such as AlphaVac and AngioVac, which saw a combined growth of 46%. The company reported an adjusted EBITDA of $3.1 million and generated $2.5 million in operating cash flow, highlighting its focus on profitability. AngioDynamics expects to achieve positive adjusted EBITDA for the full fiscal year and anticipates revenue for fiscal year 2025 to range between $282 million and $288 million, reflecting a growth of 4.2% to 6.4%. Additionally, they project Med Tech net sales to grow by 12% to 15%, with gross margins expected to be in the range of 52% to 53%.Strong Revenue Growth
Total worldwide revenue was $73 million, representing growth of approximately 9% year-over-year. Med Tech segment grew 25%.
Mechanical Thrombectomy Success
Combined growth of 46% in mechanical thrombectomy products, with AlphaVac revenue increasing by 33% and AngioVac by 51%.
Auryon Platform Growth
Auryon platform contributed $13.7 million in revenue, growing 21.8% compared to last year.
Positive NanoKnife Developments
NanoKnife probe revenue increased by 23%, with multiple key milestones achieved, including FDA clearance for prostate tissue ablation.
Improved Financial Performance
Adjusted EBITDA of $3.1 million compared to a loss of $10,000 last year, and $2.5 million in operating cash flow generated.
---
ANGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 08, 2025 | $9.40 | $12.94 | +37.66% |
| Oct 03, 2024 | $7.65 | $6.37 | -16.73% |
| Jul 16, 2024 | $5.93 | $7.51 | +26.64% |
| Apr 04, 2024 | $6.08 | $6.40 | +5.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Angiodynamics, Inc. (ANGO) report earnings?
Angiodynamics, Inc. (ANGO) is schdueled to report earning on Apr 03, 2025, TBA Not Confirmed.
What is Angiodynamics, Inc. (ANGO) earnings time?
Angiodynamics, Inc. (ANGO) earnings time is at Apr 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANGO EPS forecast?
ANGO EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.
---
